BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1685841)

  • 21. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
    Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
    J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent treatment of psoriasis with clobetasol propionate.
    Hradil E; Lindström C; Möller H
    Acta Derm Venereol; 1978; 58(4):375-7. PubMed ID: 82342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse.
    van der Vleuten CJ; van Vlijmen-Willems IM; de Jong EM; van de Kerkhof PC
    Arch Dermatol Res; 1999; 291(7-8):390-5. PubMed ID: 10482007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of palmoplantar pustulosis with intralesional triamcinolone injections.
    Goette DK; Morgan AM; Fox BJ; Horn RT
    Arch Dermatol; 1984 Mar; 120(3):319-23. PubMed ID: 6703732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
    Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
    J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
    Tosti A; Iorizzo M; Botta GL; Milani M
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
    Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
    J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometric assessment of clearance and relapse characteristics in psoriasis vulgaris after treatment with weekly clobetasol lotion under hydrocolloid occlusion versus twice-daily clobetasol ointment.
    Glade CP; van der Vleuten CJ; van Erp PE; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(2):92-9. PubMed ID: 11867965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occlusive versus nonocclusive calcipotriol ointment treatment for palmoplantar psoriasis.
    Duweb GA; Abuzariba O; Rahim M; al-Taweel M; al-Alem S; Abdulla SA
    Int J Tissue React; 2001; 23(2):59-62. PubMed ID: 11447774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
    Beutner K; Chakrabarty A; Lemke S; Yu K
    J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
    Lee CS; Koo J
    J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing.
    Volden G
    Acta Derm Venereol; 1992; 72(1):69-71. PubMed ID: 1350154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
    Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA
    Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
    Breneman D; Fleischer AB; Kaplan D; Lebwohl M; Miller B; Pariser D; Rist T; Swinyer L; Liu Y; Foley V
    J Drugs Dermatol; 2005; 4(3):330-6. PubMed ID: 15898289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis.
    Sezer E; Erbil AH; Kurumlu Z; Taştan HB; Etikan I
    J Dermatol; 2007 Jul; 34(7):435-40. PubMed ID: 17584319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study on efficacy treatment of acne vulgaris using a new method: results of a randomized double-blind trial with Acne Dressing.
    Chao CM; Lai WY; Wu BY; Chang HC; Huang WS; Chen YF
    J Cosmet Sci; 2006; 57(2):95-105. PubMed ID: 16688374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of therapy-resistant atopic dermatitis with clobetasol propionate and a hydrocolloid occlusive dressing.
    Volden G
    Acta Derm Venereol Suppl (Stockh); 1992; 176():126-8. PubMed ID: 1476024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
    Andres P; Poncet M; Farzaneh S; Soto P
    J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hand dermatosis: a comparative study of a topical glucocorticoid ointment vs solution occluded with a new thin hydrocolloid dressing.
    Beitner H
    Acta Derm Venereol; 1996 Sep; 76(5):408-9. PubMed ID: 8891026
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
    Engin B; Oguz O
    Int J Dermatol; 2005 Apr; 44(4):337-9. PubMed ID: 15811091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.